Moving to the Future of Clinical Trials – How Innovation and Technology are Shaping Precision Medicine
Precision medicines are those which target known genetic, molecular or cellular markers and can be tailored to the individual characteristics of individuals, helping in providing a more personalized approach to patients. Precision medicine often involves the application of “omic” analyses and systems biology to molecularly understand the basis of a patient’s disease. This understanding would potentially point to targeted treatments to limit disease progression. The patient’s response is then tracked, often using surrogate measures, and the treatment refined to the patient’s response. A key advantage of precision medicines is their ability to better predict how individuals will respond to therapies. In practice, examples where this drug discovery has led to innovations are currently seen mainly in oncology, but the potential to stratify patients by disease subtypes holds much promise in improving care and often requires modification of traditional trial designs and innovation in order to better evaluate these medicines. This presentation will share how precision medicine is leading to changes in both the concept and implementation of clinical trials. In this session,Linda Malkas, Ph.D., dean of translational science, Professor in Molecular Oncology and associate chair in the Department of Molecular and Cellular Biology at City of Hope will explore the impact of new technology, innovation and approaches from precision medicine in the clinical trial process.